A 1-h enzyme-linked immunosorbent assay (Rubestat) was developed for rubella virus immunoglobulin G detection. The assay used phenolphthalein monophosphate as the substrate, which, when developed, can easily be read visually. Rubestat compared very favorably to hemagglutination inhibition and commercial enzymelinked immunosorbent assays in its ability to determine immune status. Rubestat demonstrated >97% specificity, sensitivity, and accuracy as compared with other methodologies at 10 different laboratories. The Rubestat index values were precise, with coefficients of variation for intra-and interassay variation of less than 10%. Mean index values had a linear correlation with hemagglutination inhibition titers (r2 > 0.97). A population distribution of index values illustrated two distinct bell-shaped curves representing the positive and negative populations. Studies of acute and convalescent serum pairs showed Rubestat to be as accurate as hemagglutination inhibition in determining seroconversion.
The detection of antibody to rubella virus was first accomplished by neutralization (13, 22) and later by indirect immunofluorescence (2) , complement fixation (15) , and hemagglutination inhibition (HAI) (17) . Historically, the HAI test has been the method of choice in rubella serology. In 1975, Voller and Bidwell (21) described an enzyme-linked immunosorbent assay (ELISA) for measuring rubella-specific antibody. Voller and Bidwell demonstrated that ELISA had several advantages over HAI, whereas it retained sensitivity and specificity comparable to HAI. Since the original observation, a number of other authors have described a variety of ELISA procedures with different enzyme conjugates and different solid phases (6, (8) (9) (10) (11) 20) . These procedures have had a number of limitations, including the time required to perform the test, usually 2 to 5 h, the requirement for equipment, and the need for specialized technicians. This paper presents the results of a multicenter study in which a standardized ELISA test with a 1-h protocol was evaluated relative to both standard HAI methods and commercially available enzyme immunoassay kits.
MATERIALS AND METHODS Clinical sera. A sampling of 2,727 sera was assayed by both Rubestat and HAI or commercial ELISA at 10 different laboratories. The samples were sera routinely submitted to each center for immune status testing for rubella virus. The age and sex of the individuals were not available. Any sera showing descrepant results were retested in both test systems, during a routine run. The results of the retesting were considered final. Acute-and convalescent-phase serum pairs from 18 patients with natural rubella infection and 28 patients who received rubella vaccine were assayed at center 11, St. Luke's-Roosevelt Hospital Center.
HAI and RUBAZYME tests. Four different HAI methods were performed in this study. Centers 1 and 2 utilized human 0 erythrocytes (RBCs) with heparin-MnCl2 as a serum pretreatment (Ortho), whereas centers 3, 4, and 11 used the same pretreatment but used chick RBCs (12) . Center Antigen. The rubella virus (Gilchrist strain) was cultured in roller bottles of mycoplasma-free BHK-21 cells, maintained with Eagle minimal essential medium supplemented with 2 mM L-glutamine per ml and 50 p.g of gentamicin (Whittaker M. A. Bioproducts) per ml. The antigen was extracted with alkaline buffers as previously described (14) . The antigen was further purified by ultracentrifugation and was ether-treated for 1 h. After purification, the antigen was stored at -70°C.
ELISA. The ELISA assay was performed in Removawell microtiter plates, (Dynatech Laboratories, Inc., Alexandria, Va.). Optimal antigen concentration was determined by block titration of antigen and conjugate. The appropriate antigen dilution was coated on the plates by using carbonate buffer as described by Voller and Bidwell (21 Fig. 1 . Index values for 536 sera from center 5 were plotted relative to the frequency of each index value. Approximate best-fit curves were drawn to enclose the data points. Two bell-shaped curves were evident, one for the positive population and one for the negative population. There was also a sharp delineation between the two populations. Quantitation ability of Rubestat. Rubestat index values were determined for serial twofold dilutions of six positive sera. The index values were linear with the log2 of dilution as analyzed by linear regression (Table 6 ), thus allowing for linear quantitation from a single serum dilution. As previously described (1, (9) (10) (11) , critical ratios for ELISA kits produced by Whittaker M. A. Bioproducts are interpreted as highly indicative of an active infection if the values are .1.47. These values are equivalent to a fourfold or greater increase in HAI titer. Critical ratios are presented in Table 7 for 18 patients with natural rubella virus infection. In every case, there was a fourfold increase in HAI titer and a critical ration of .1.47. In three cases the acute sera were HAI positive and Rubestat negative. All three sera were shown to be IgM positive by sucrose density gradient separation. Critical ratios for 28 patients who received rubella virus vaccine are included in Table 8 . In all cases the critical ratio was .1.47. In one instance the Rubestat was positive for the convalescent serum, and the HAI was negative. This serum was not retested by another method. DISCUSSION The data presented on sensitivity, specificity, and accuracy illustrate that the Rubestat assay is substantially equivalent to HAI for determining immune status to rubella virus. The data from each individual center fluctuated in terms of sensitivity and specificity. This was probably due in part to the use of different methods for the HAI testing at the centers, thus making one HAI test more sensitive than another. Differences in HAI assays from center to center have been reported in Centers for Disease Control surveys (18) and College of American Pathologists surveys (16) . Therefore, it is impossible to standardize an assay to obtain 100% correlation at all laboratories. It has been reported that ELISA assays can be standardized to be more sensitive than HAI (4, 7). However, there are not enough data illustrating that low levels of antibody, undetectable by HAI, are actually protective against rubella infection. Until more clinical information becomes available regarding these patients, the Rubestat assay will yield results that are comparable to those obtained by the HAI method recommended by the Centers for Disease Control (12) . As could be expected, the sensitivity, specificity, and accuracy of Rubestat and Rubazyme were essentially equal.
Mean Rubestat index values were shown to increase linearly with HAI titers; however, the values were quite varied for each titer. This phenomenon has been reported for rubella (10, 19, 23) and for measles virus serology (1), due to the different populations of antibodies measured by the assays. The HAI measures only antibody to rubella antigen that hemagglutinates, whereas theoretically the ELISA would detect any IgG antibody with specificity to rubella virus. The Rubestat index values were shown to correlate with Rubazyme index values; however, the sera that reacted strongly in the Rubazyme assay plateaued in O.D. This agrees with a previous report that sera with HAI titers of >64 were difficult to discriminate in the Rubazyme assay (C. Kroft, G. J. Haller, and J. A. Franco, Abstr. Annu. Meet. Am. Soc. Microbiol. 1983, C115, p. 330).
The population distribution curve of index values simulated a normal population of patients. Two bell-shaped curves were shown, signifying a normal distribution of values for the positive and negative populations. There was a clear-cut separation between the two populations, demonstrating that the assay delineates positive sera from negative sera. As with any assay, there will be a small percentage of sera near the immune cutoff level, for which it will be more difficult to determine immune status. In summary, the Rubestat assay is a viable alternative to the labor-intensive HAI assay and other more-time-consuming ELISA assays.
